These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32804837)

  • 61. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
    Su J; Zhou X; Chen H; Hao B; Zhang W; Zhang G
    Medicine (Baltimore); 2017 Feb; 96(7):e5859. PubMed ID: 28207505
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for
    Kim SJ; Chung JW; Woo HS; Kim SY; Kim JH; Kim YJ; Kim KO; Kwon KA; Park DK
    World J Gastroenterol; 2019 Dec; 25(46):6790-6798. PubMed ID: 31857780
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
    Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
    Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.
    Luo L; Ji Y; Yu L; Huang Y; Liang X; Graham DY; Lu H
    Dig Dis Sci; 2020 Dec; 65(12):3639-3646. PubMed ID: 32020360
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
    Fakheri H; Bari Z; Sardarian H
    Helicobacter; 2012 Aug; 17(4):264-8. PubMed ID: 22759325
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey.
    Yozgat A; Kasapoğlu B; Demirci S; Coşkun Sökmen F
    Rev Esp Enferm Dig; 2021 Jul; 113(7):490-493. PubMed ID: 33233910
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating
    Chi J; Xu C; Liu X; Wu H; Xie X; Liu P; Li H; Zhang G; Xu M; Li C; Wang C; Song F; Yang M; Wu J
    Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558883
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial.
    Hsu PI; Chen KY; Tai WC; Yang JC; Tsay FW; Liu YH; Chen CL; Lee CL; Yeh HZ; Kuo CH; Chuah SK; Lee HC; Shie CB; Shiu SI; Kao JY; Yamaoka Y; Graham DY; Wu DC;
    Am J Gastroenterol; 2023 Jul; 118(7):1184-1195. PubMed ID: 36940437
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
    Chen Q; Zhang W; Fu Q; Liang X; Liu W; Xiao S; Lu H
    Am J Gastroenterol; 2016 Dec; 111(12):1736-1742. PubMed ID: 27670603
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication.
    Ozturk O; Doganay L; Colak Y; Yilmaz Enc F; Ulasoglu C; Ozdil K; Tuncer I
    Arab J Gastroenterol; 2017 Jun; 18(2):62-67. PubMed ID: 28601610
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
    Wang Z; Wu S
    Singapore Med J; 2012 Apr; 53(4):273-6. PubMed ID: 22511052
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
    Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
    Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance.
    Huang TH; Yang SC; Tai WC; Liang CM; Kuo CM; Yao CC; Wu CK; Kuo YH; Chou YP; Lee CH; Wu KL; Chuah SK
    Biomed J; 2021 Dec; 44(6 Suppl 2):S275-S281. PubMed ID: 35292265
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
    Yoon K; Kim N; Lee JW; Yoon H; Shin CM; Park YS; Lee DH
    Helicobacter; 2020 Jun; 25(3):e12685. PubMed ID: 32141173
    [TBL] [Abstract][Full Text] [Related]  

  • 77. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
    Nyssen OP; Perez-Aisa A; Castro-Fernandez M; Pellicano R; Huguet JM; Rodrigo L; Ortuñ J; O ; Gomez-Rodriguez BJ; Pinto RM; Areia M; Perona M; Nuñez O; Romano M; Gravina AG; Pozzati L; Fernandez-Bermejo M; Venerito M; Malfertheiner P; Fernanadez-Salazar L; Gasbarrini A; Vaira D; Puig I; Megraud F; O'Morain C; Gisbert JP;
    United European Gastroenterol J; 2021 Feb; 9(1):38-46. PubMed ID: 33176617
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.
    Fakheri H; Taghvaei T; Hosseini V; Bari Z
    Helicobacter; 2012 Feb; 17(1):43-8. PubMed ID: 22221615
    [TBL] [Abstract][Full Text] [Related]  

  • 79. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
    Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
    Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
    Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.